AU2020253828A1 - GHRH or analogues thereof for use in treatment of hepatic disease - Google Patents
GHRH or analogues thereof for use in treatment of hepatic disease Download PDFInfo
- Publication number
- AU2020253828A1 AU2020253828A1 AU2020253828A AU2020253828A AU2020253828A1 AU 2020253828 A1 AU2020253828 A1 AU 2020253828A1 AU 2020253828 A AU2020253828 A AU 2020253828A AU 2020253828 A AU2020253828 A AU 2020253828A AU 2020253828 A1 AU2020253828 A1 AU 2020253828A1
- Authority
- AU
- Australia
- Prior art keywords
- ghrh
- pharmaceutically acceptable
- hexenoyl
- acceptable salt
- frans
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826284P | 2019-03-29 | 2019-03-29 | |
| US62/826,284 | 2019-03-29 | ||
| US201962861187P | 2019-06-13 | 2019-06-13 | |
| US62/861,187 | 2019-06-13 | ||
| PCT/US2020/025180 WO2020205498A1 (en) | 2019-03-29 | 2020-03-27 | Ghrh or analogues thereof for use in treatment of hepatic disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2020253828A1 true AU2020253828A1 (en) | 2021-10-28 |
Family
ID=72607731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2020253828A Abandoned AU2020253828A1 (en) | 2019-03-29 | 2020-03-27 | GHRH or analogues thereof for use in treatment of hepatic disease |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10799562B1 (https=) |
| EP (1) | EP3947426A4 (https=) |
| JP (1) | JP2022527190A (https=) |
| KR (1) | KR20210145226A (https=) |
| CN (1) | CN113646327A (https=) |
| AU (1) | AU2020253828A1 (https=) |
| CA (1) | CA3133319A1 (https=) |
| IL (1) | IL286703A (https=) |
| SG (1) | SG11202110469PA (https=) |
| WO (1) | WO2020205498A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202110469PA (en) | 2019-03-29 | 2021-10-28 | Massachusetts Gen Hospital | Ghrh or analogues thereof for use in treatment of hepatic disease |
| CN115884783A (zh) * | 2020-07-05 | 2023-03-31 | 瑟瑞技术公司 | Ghrh类似物的低剂量药物组合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101678083A (zh) * | 2007-04-04 | 2010-03-24 | 瑟瑞技术公司 | Ghrh分子的药物制剂 |
| US9163091B2 (en) * | 2007-05-30 | 2015-10-20 | Lpath, Inc. | Compositions and methods for binding lysophosphatidic acid |
| US20150174207A1 (en) * | 2013-12-24 | 2015-06-25 | University Of Miami | Methods for treating cancer with ghrh agonists |
| US20170105996A1 (en) * | 2015-10-16 | 2017-04-20 | Teva Pharmaceutical Industries, Ltd. | Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine |
| WO2017181277A1 (en) * | 2016-04-19 | 2017-10-26 | Griffon Pharmaceuticals Inc. | Pegylated bioactive peptides and uses thereof |
| KR20200121308A (ko) * | 2018-02-14 | 2020-10-23 | 루모스 파마, 인크. | 비알코올성 지방간 질환 및 비알코올성 지방간염 치료용 조성물 |
| SG11202110469PA (en) * | 2019-03-29 | 2021-10-28 | Massachusetts Gen Hospital | Ghrh or analogues thereof for use in treatment of hepatic disease |
| WO2022093757A1 (en) * | 2020-10-30 | 2022-05-05 | The General Hospital Corporation | Kits, reagents and methods for the assessment of liver diseases |
| US20220152012A1 (en) * | 2020-11-16 | 2022-05-19 | The Regents Of The University Of California | Methods for regressing or reversing fibrosis and/or liver cirrhosis in a subject in need thereof using high-dose niacin, or a niacin analog thereof |
-
2020
- 2020-03-27 SG SG11202110469PA patent/SG11202110469PA/en unknown
- 2020-03-27 CN CN202080025127.2A patent/CN113646327A/zh active Pending
- 2020-03-27 CA CA3133319A patent/CA3133319A1/en active Pending
- 2020-03-27 KR KR1020217034940A patent/KR20210145226A/ko not_active Ceased
- 2020-03-27 EP EP20784029.9A patent/EP3947426A4/en not_active Withdrawn
- 2020-03-27 JP JP2021557925A patent/JP2022527190A/ja active Pending
- 2020-03-27 AU AU2020253828A patent/AU2020253828A1/en not_active Abandoned
- 2020-03-27 WO PCT/US2020/025180 patent/WO2020205498A1/en not_active Ceased
- 2020-03-27 US US16/832,128 patent/US10799562B1/en active Active
- 2020-09-11 US US17/018,878 patent/US10946073B2/en active Active
-
2021
- 2021-02-08 US US17/170,579 patent/US11738066B2/en active Active
- 2021-09-26 IL IL286703A patent/IL286703A/en unknown
-
2023
- 2023-07-12 US US18/351,169 patent/US12233107B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10946073B2 (en) | 2021-03-16 |
| US11738066B2 (en) | 2023-08-29 |
| US10799562B1 (en) | 2020-10-13 |
| EP3947426A4 (en) | 2023-01-04 |
| WO2020205498A1 (en) | 2020-10-08 |
| EP3947426A1 (en) | 2022-02-09 |
| JP2022527190A (ja) | 2022-05-31 |
| US20240091316A1 (en) | 2024-03-21 |
| KR20210145226A (ko) | 2021-12-01 |
| US20200405816A1 (en) | 2020-12-31 |
| CN113646327A (zh) | 2021-11-12 |
| US12233107B2 (en) | 2025-02-25 |
| SG11202110469PA (en) | 2021-10-28 |
| IL286703A (en) | 2021-10-31 |
| US20210177943A1 (en) | 2021-06-17 |
| US20200306345A1 (en) | 2020-10-01 |
| CA3133319A1 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12233107B2 (en) | GHRH or analogues thereof for use in treatment of hepatic disease | |
| US20140135263A1 (en) | Rapid Acting Injectable Insulin Compositions | |
| US20050112093A1 (en) | Combination therapy for HCV infection | |
| WO2013050378A1 (en) | Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract | |
| KR20040053291A (ko) | 오메가 인터페론을 이용한 질환 치료 방법 | |
| Bruno et al. | Oral LPCN 1148 improves sarcopenia and hepatic encephalopathy in male patients with cirrhosis: A randomized, placebo-controlled phase 2 trial | |
| KR20240176455A (ko) | 시클로덱스트린을 포함하는 약학적 제형 | |
| KR20090020646A (ko) | 4기 악성 흑색종의 치료를 위한 약제의 제조를 위한 티모신알파 1의 용도 | |
| WO2025096262A1 (en) | Mdm2 degraders and uses thereof | |
| TW202034955A (zh) | 使用免疫調節治療癌症之新穎方法 | |
| KR20210079275A (ko) | 고콜레스테롤 관련 병으로 치료 받고 있는 환자에서의 당뇨병의 위험 감소 방법 | |
| US20200197494A1 (en) | Peptide compositions and methods of use | |
| US20130079416A1 (en) | Homeopathic medicament comprising phenacetin for the treatment of cancer | |
| US20230270865A1 (en) | Low-dose pharmaceutical compositions of ghrh analogs and uses thereof | |
| EP4643862A1 (en) | Pharmaceutical composition and use thereof | |
| WO2026026911A1 (zh) | 一种二肽衍生物的应用 | |
| CN120078888A (zh) | 一种治疗肺癌的药物组合物及其应用 | |
| CN116407614A (zh) | 一种新型三激动剂创新生物药物的稳定制剂 | |
| CN117018197A (zh) | 促进dock11表达的试剂作为治疗神经病理性疼痛药物的应用 | |
| Bavec | Insulin, Other Hypoglycaemic Drugs, and Glucagon | |
| CN115315268A (zh) | 用于治疗非酒精性脂肪性肝炎(nash)的组合物和方法 | |
| HK1129840A (en) | Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma | |
| WO2015036507A1 (en) | Use of cabazitaxel in patients with metastatic nsclc progressing after docetaxel-based treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |